PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®-platform. Cyclops® is a proprietary, fully developed, breath-actuated, easy-to-use, pre-filled, single-use DPI, targeting systemic and respiratory diseases with a significant unmet medical need.
PureIMS is pursuing commercial and business development & licensing opportunities by offering its Cyclops® platform, to co-develop products with partners who are pursuing NCEs, NBEs and/or repurposed inhaled medicines of choice, for local or systemic application. Currently, we are actively investigating the versatile applications of Cyclops® across diverse fields, encompassing the development of (pro-)drugs, mucosal vaccination, lung cancer chemotherapy and diagnostic pulmonary biomarkers.
PureIMS has GMP facilities for the clinical-scale manufacturing of Cyclops®-based products. The Cyclops®-formulation process is scalable and the company has built strong relationships with several major developers of market-scale production lines.
In addition, PureIMS is offering partnering opportunities for its pipeline programs, as described below.
PureIMS
Ceintuurbaan Noord 152
Roden NZ 9301
Netherlands
+31 (0)50 – 20 533 25
pureims.com
info@pureims.com
PureIMS
“How can we offer patients with a serious condition like cystic fibrosis an efficient and much more convenient method of administering medication via the airways?" This question was asked by developers in collaboration with scientists from the University of Groningen and resulted in the foundation of PureIMS.
Watch PureIMS’ short company introduction video.
More Info
Cyclops
Cyclops® is a proprietary, fully developed, breath-actuated and highly efficient, easy-to-use, pre-filled, single-use dry powder inhaler (DPI), targeting systemic and respiratory diseases with a significant unmet medical need.
Cyclops® is available in single & multi use versions, having numerous advantages compared to standard-of-care DPIs across key therapeutic areas.
PureIMS is offering its Cyclops® platform for in-licensing activities.
More Info
Levodopa Cyclops®
Levodopa Cyclops®, PureIMS’ lead candidate, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease in the US following the 505(b)(2) regulatory pathway.
A Phase II PoC study showed a significant and clinically meaningful change in MDS-UPDRS Part III motor score within 20 minutes.
Levodopa Cyclops® is open for partnering.
More Info
Colistin Cyclops®
Colistin Cyclops® is administered and reimbursed under a named patient program for the treatment of cystic fibrosis or bronchiectasis patients in the Netherlands. Close to 70,000 doses have been provided.
In a retrospective study, an average adherence rate of 92.5% was observed, where 71.4% of the patients preferred Cyclops® over nebulization.
Colistin Cyclops® is open for partnering.
More Info
Epinephrine Cyclops®
Epinephrine Cyclops® is being developed as a non-invasive, fast and reliable treatment of severe allergic reactions and impending anaphylaxis, including local treatment of symptoms in the airways and oropharyngeal region.
In a Phase 1 clinical trial inhaled doses resulted in a much shorter and less variable time to maximum plasma concentration than intramuscular epinephrine.
Epinephrine Cyclops® is open for partnering. More Info
